Grants for Private Institutions Of Higher Education

The Texas Health and Human Services Commission invites applications for funding under the Aging and Disability Resource Center (ADRC) Services grant. This grant supports the establishment and operation of ADRCs in seven designated Planning and Service Areas (PSAs) across Texas. These centers aim to provide a comprehensive, streamlined access system for older adults and individuals with disabilities, facilitating easier connection to long-term services and supports. The grant focuses on enhancing several core services, including specialized information, referral and assistance services, respite care referrals, local contact agency services for community living transitions, housing navigator services to increase accessible and affordable housing, and outreach activities for Medicare-related benefits. This initiative is a part of the broader No Wrong Door system, which involves multiple federal agencies to improve the quality and accessibility of long-term care and supports. The project stresses collaboration with local agencies and community organizations to ensure a wide-reaching impact.

The FY24 PCRP Implementation Science Award supports studies that are expected to bridge the gap between research, practice, and policy through establishment of a knowledge base of interventions, clinical practices/guidelines, tools, and policies that can be deployed to targeted populations at the appropriate time and point of need. For the purposes of this funding opportunity, an implementation science study accesses strategies used and develops tools to enhance the systematic uptake of evidence-based health interventions into clinical and/or community settings in order to improve patient outreach, patient outcomes, and/or the effectiveness of health care.Impact: Research supported by the Implementation Science Award is expected to have the potential for major, near-term impact that will accelerate the widespread adoption of evidence-based practices in prostate cancer care, prevention, and survivorship. Applications are expected to identify the prostate cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Applications must also include a detailed research transition plan that articulates the pathway to moving the projects findings to the next phase for widespread clinical impact after successful completion of the award. Research transition plans are encouraged to consider future strategies targeting the patient, physician/provider, community, and/or healthcare system levels as applicable.Community Engagement: Applications are required to include members of the targeted population and/or community in the development and execution of the research project where appropriate. The research team must include one or more prostate cancer consumer advocate(s) or member(s) of the community, who will be integral throughout the planning and performance of the research project. Consumer advocates and/or community-based members should be involved in the development of the research question, project design, oversight, recruitment, and evaluation and dissemination of outcomes, as well as other significant aspects of the proposed project. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings; communication between the research team and the community should be frequent and bidirectional. The consumer advocates can be individuals who have been diagnosed with prostate cancer, a direct caregiver for someone who has been diagnosed with prostate cancer, or other representatives from the targeted community who are positioned to effect change. The consumer advocates and/or community-based members should have a high level of knowledge of current prostate cancer issues and the appropriate background in prostate cancer research and/or clinical care to contribute to the project or be otherwise positioned within the target community to effect changes in behavior based on projected outcomes. A list of implementation science resources and community or advocacy organizations is provided at the end of the Implementation Science Award Information section.Health Equity and Disproportionately Affected Populations: Regardless of the FY24 PCRP Overarching Challenge(s) being addressed, all research projects are strongly encouraged to consider health equity (e.g., access to evidence-based care) and/or have a focus on addressing the needs of disproportionately affected populations in the application.Research Scope: The Implementation Science Award mechanism is intended to fund studies including, but not limited to, the following: Small-scale clinical trials (up to phase 2) that contain clear reporting and implementation strategies to narrow the research-to-practice timeline and improve care for prostate cancer survivors, particularly within disproportionately affected populations Interventions that focus on behavioral or lifestyle changes at the patient, provider, community, and/or policy level Comparative effectiveness research establishing the benefits and harms of emerging or standard-of-care interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to health care access across the cancer care continuum Altering the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines.Preliminary data to support the scientific rationale and feasibility of the research approaches are required. These preliminary data do not need to have been generated solely in prostate cancer. The inclusion of additional preliminary data to support the clinical relevance of the idea is strongly encouraged.Investigators proposing a clinical trial are highly encouraged to consider leveraging the PCRP Prostate Cancer Clinical Trials Consortium (https://pcctc.org) to facilitate the rapid initiation and completion of the trial.Correlative studies that are associated with ongoing clinical trials, and preclinical studies involving the use of animals do not meet the intent of the FY24 PCRP Implementation Science Award.Partnering Principal Investigator (PI) Option: The FY24 PCRP Implementation Science Award encourages applications that include meaningful and productive collaborations between two investigators. The PIs may have expertise in similar or disparate scientific and/or clinical disciplines, but each PI is expected to bring distinct contributions to the application. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 PCRP prioritiesInnovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.A Clinical Trial Option allows for studies proposing small-scale clinical trials with a focus on implementation science. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Applications proposing a clinical trial are expected to provide detailed plans for initiating the clinical study within the first year, including U.S. Food and Drug Administration (FDA) Investigational New Drug/Investigational Device Exemption application submission plans, within 60 days of the award.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Implementation Sciences Resources: Potential applicants for this award are encouraged to seek collaborations and access to appropriate study populations through the following (or similar) resources: CDMRP: Search the CDMRP awards database at https://cdmrp.health.mil. The North Carolina Louisiana Prostate Cancer Project (PCaP): The PCaP was supported by the PCRP to conduct prostate cancer health disparity studies and developed a large biorepository of health disparity-related epidemiological data and biospecimens that may be requested for use by the research community. Information on PCaP investigators, data, and specimens is available at https://pcap.bioinf.unc.edu. National Cancer Institute Center to Reduce Cancer Health Disparities: Search for health disparity research and researchers at https://crchd.cancer.gov/index.html. National Institute on Minority Health and Health Disparities (NIMHD), National Institutes of Health (NIH), Community-Based Participatory Research (CBPR) Initiative: Contact the NIMHD at https://www.nimhd.nih.gov/programs/extramural/community-based-participatory.html for information on current CBPR programs and scientists and communities engaged in health disparity research. Cancer Prevention and Control Research Network (CPCRN): Contact the CPCRN at https://cpcrn.org/ for information on community participatory research to reduce cancer in disproportionately affected populations. Health Resources and Services Administration, Office of Minority Health: Search for health disparity programs and funded investigators at https://www.hrsa.gov/index.html. NIH Research Portfolio Online Reporting Tool (NIH RePORTER): Search for NIH awards at https://projectreporter.nih.gov/reporter.cfm. Defense Technical Information Center (DTIC): Search for Department of Defense (DOD) and other government-funded investigators through DTIC Technical Reports at https://discover.dtic.mil/. National Library of Medicine, NIH, PubMed: Search for investigators publishing studies on prostate cancer health disparities at https://www.ncbi.nlm.nih.gov/pubmed. U.S. Department of Education: Search for institutions that may have increased access to disproportionately affected populations at https://www2.ed.gov/about/offices/list/ocr/edlite-minorityinst.html. International Cancer Research Partnership: Search for investigators and studies relevant to health disparity that are supported by cancer research funders from several countries including the United States, European Union, United Kingdom, and Canada at https://www.icrpartnership.org. National Coalition for LGBT Health: For more information on programs focused on Lesbian, Gay, Bisexual, and Transgender (LGBT) research, policy, education, and training, search https://www.healthlgbt.org. National LGBT Cancer Network: To obtain more information, search https://www.cancer-network.org.In addition, the following is a list of potential community and/or advocacy organizations that applicants may find helpful to satisfy the requirement for community engagement within their proposed studies: the American Indian Health Care Association, National African American Outreach Program of the Patient Advocate Foundation, National Alliance for Hispanic Health, National Medical Association, National Rural Health Association, and Prostate Health Education Network, as well as international organizations such as the African-Caribbean Cancer Consortium, African Organization for Research and Training in Cancer, Europa Uomo, European Cancer Patient Coalition, Global Prostate Cancer Alliance, Malecare, Men of African Descent and Carcinoma of the Prostate Consortium, Prostate Cancer Transatlantic Consortium, Urban League, and The Prostate Net.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 PCRP Implementation Science Award should not exceed $2.0M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $9.6M to fund approximately three PCRP Implementation Science Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The National Endowment for the Arts (NEA) is proud to support the nations arts sector with grant opportunities so that together we can help everyone live more artful lives. The arts contribute to our individual well-being, the well-being of our communities, and to our local economies. The arts are also crucial to helping us make sense of our circumstances from different perspectives as we emerge from the pandemic and plan for the future. Grants for Arts Projects is our largest grants program for organizations, providing comprehensive and expansive funding opportunities for communities. Through project-based funding, the program supports opportunities for public engagement with the arts and arts education, for the integration of the arts with strategies promoting the health and well-being of people and communities, and for the improvement of overall capacity and capabilities within the arts sector. We welcome applications from a variety of eligible organizations, including first-time applicants; from organizations serving rural, urban, suburban, and tribal communities of all sizes; and from organizations with small, medium, or large operating budgets. An organization may submit only one application under these FY2025 Grants for Arts Projects guidelines. If an organization applies to the Challenge America category, it may not also apply to the Grants for Arts Projects category. The National Endowment for the Arts support of a project may start on or after June 1, 2024. Generally, a period of performance of up to two years is allowed.

he DOE SC program in High Energy Physics (HEP) hereby announces its interest in receiving interdisciplinary applications for open scientific research on Quantum Information Science (QIS) Enabled Discovery (QuantISED) to further the HEP mission to understand how the universe works at its most fundamental level. Successful applications will help define an exploratory program where innovative solutions for scientific discovery are developed and deployed to advance HEP science drivers and contribute to QIS research and technology for public benefit.The QIS subprogram within HEP has been developed over the last few years with a series of workshops, followed by funding opportunities in 2018 and 2019, and is aligned with a broader SC initiative in QIS and coordinated with various national and interagency QIS programs, including the National QIS Research Centers. Cross-cutting the traditional frontiers and thrusts of the HEP program, the QIS subprogram exploits the interdisciplinary nature of QIS and associated partnerships for exploratory, early-stage research aimed at high impact discoveries aligned with HEP science goals, but also driving developments in foundational QIS and related scientific and technology research areas.Such research is intended to create public benefit within HEPs Congressionally-authorized mission space by increasing human understanding of the physical universe and driving relevant developments of advanced technologies that support that mission.

The PRP EIRA supports research opportunities for investigators in the early stages of their careers. The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.

SUMMARY: The U.S. Embassyin the PhilippinesPublic Affairs Section (PASPhilippines) of the U.S. Department of State is pleased to announce thatwe are considering proposals for the operational and program development workforthe 2024 American Spaces Philippines Conference. Our funding goals, strategic themes, and processes for submitting grant proposals are all outlined in this notice. Please read carefully and follow all instructions. This notice is subject to the availability of funding. PROGRAM DESCRIPTION PAS Philippines invites individuals, non-profit organizations, and non-government organizations to submit proposals to implement the 2024 American Spaces Philippines Conference. The event is a three-day conference with representatives from American Spaces partner institutions. The intent of this program is to bring together university leaders and American Corner staff members from across the country for a strategic planning session, networking, and capacity-building activities. The Grantee will support the Embassy by fulfilling the logistical, travel, and administrative needs of the conference, as well as providing constructive inputs on the program of the conference. The budget should not be more than $40,000 in total. The successful Grantee must have demonstrable experience in conference management (minimum size of 40 participants), events planning, and high-level customer relations. Grantee must also demonstrate their ability to responsibly manage funds, coordinate logistics, and execute the program plan within the expected timeline. Examples of activities include, but are not limited to: Programming Develop 3 learning sessions that will build the skills of the participants in the areas of project designing, partnership building, and program management. Organize a small exhibit in the venue featuring the projects of the participants Organize a team-building activity for the participants Events Planning Scout and book a conference venue within Luzon, Visayas, or the City of Davao that is accessible to the airport, and major transportation hubs. Coordinate with a hotel for the reservations of all participants, including the processing of required down payments. Prepare financial reports and liquidations of project expenses, including hotel, equipment, food and beverage suppliers, and any relevant subcontractors. Coordinate and arrange a full-board meal for organizers and participants including the accommodation of those with special diets (halal, vegetarian, etc). Arrange overall logistics and ensuring the availability of high-speed wifi, computers, high-resolution web cams, and microphones to accommodate hybrid sessions Organize the plenary hall, any breakout rooms and prepare necessary workshop materials Design, and produce conference kits, and marketing materials such as pull-up banners, event shirts, tokens, tote bags etc. Travel Arrangements Coordinate and book flight itineraries with varying origin destinations. Arrange and book all airport transfer services for participants. Issue plane tickets, room reservations and airport transfer service to each participant. Arrange land transportation for participants as necessary. Organize and pay the travel allowance of the participants. PRIORITY PROGRAM AREAS The program should empower American Spaces partners to increase knowledge on the following priority program areas: Girls/Women in Science, Technology, Engineering and Math (STEM) Entrepreneurship Innovation and Artificial Intelligence Peace Education Democracy and Human Rights Climate Change and Environmental Protection Participants and Audiences: Target audiences include university presidents from American Spaces-hosting institutions, and library directors and staff. Please note that the following types of programs are NOT eligible for funding: Programs relating to partisan political activity; Charitable, humanitarian, or development activities; Construction programs; Programs that support specific religious activities; Fund-raising campaigns or programs charging a fee for participation; Lobbying for specific legislation or programs; Scientific research; Programs intended primarily for the growth or institutional development of an organization; or Programs that duplicate existing programs; Activities that take place in the United States and its territories; Programs with alcohol, excessive meals, refreshments, or entertainment; and Individual scholarships.

The Pfizer Fellowship Grant for Transthyretin Cardiac Amyloidosis is a competitive grant initiative aimed at advancing the professional development of healthcare professionals specializing in the diagnosis and management of ATTR cardiac amyloidosis. This grant is dedicated to enhancing academic and clinical understanding of the disease through research and education. Offered to U.S.-based academic institutions, the program supports fellowship roles for Cardiologists or Heart Failure Advanced Practice Providers, emphasizing a balance of clinical practice, research, and educational outreach. The grant ensures that the supported activities are independent of Pfizer’s commercial interests, focusing on fostering substantial advancements in the field of cardiac health.

The FY24 DMDRP CTRA mechanism supports advanced translational research that will accelerate the movement of promising ideas in DMD research into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between applied and clinical research. As such, applications must include preliminary and/or published data relevant to DMD to support the proposed research project.This mechanism is intended to support established projects that have moved beyond the realm of basic research and proof of concept studies and have the potential to result in a near-term impact in clinical research or the clinic. Research projects investigating therapies that will be efficacious across the life span, including infants, toddlers, and non-ambulatory individuals, are strongly encouraged. Pilot, proof-of-principle clinical trials, and correlative studies to better inform development of drugs, devices, and other interventions are allowed.Early-Career Partnering PI Option: The FY24 DMDRP encourages applications that include meaningful and productive collaborations between investigators. In an effort to promote enhanced research capacity within the DMD field, the FY24 CTRA includes an option for an Early-Career Partnering Principal Investigator (PI). The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Early-Career PI will be identified as the Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.The FY24 DMDRP CTRA offers two funding levels (refer to Section II.D.5 Funding Restrictions). Only one funding level category may be chosen per application, and the choice of application category is at the discretion of the applicant. The following are generalized descriptions of the scope of the research appropriate for each funding level:Funding Level 1: Funding Level 1 is intended to support smaller, less complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $650,000.Funding Level 2: Funding Level 2 is intended to support larger, more complex preclinical and/or clinical research. Pilot clinical trials are allowed. The proposal/applications direct costs budgeted for the entire period of performance should not exceed $1.35M.Additionally, both funding levels will support an Early-Career Partnering PI Option at the same maximum direct costs and periods of performance, respectively.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Both pilot clinical trials and clinical research are permitted under this mechanism.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.All investigators applying to FY24 DMDRP funding opportunities and conducting clinical research are encouraged to consult the Strategies to Promote Diversity in Muscular Dystrophy Research Participation developed by the MDCC.

The FY24 DMDRP IDA promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMD. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.New Investigators: The FY24 DMDRP IDA mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent) or applications from established investigators new to DMD research.The New Investigator Early Stage category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators.The New Investigator Transitioning category is designed to allow investigators in an area other than muscular dystrophy, at or above the level of Assistant Professor, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator Early Stage category or New Investigator Transitioning category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in DMD research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PIs expertise to best address the research question. All applicants for the New Investigator categories must meet the specific eligibility criteria described in Section II.C, Eligibility Information.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required. Preliminary data may include unpublished results from the laboratory of the PI, research team or collaborators named on the application.Key elements of this award are as follows:Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward improving outcomes for individuals with DMD.It is the responsibility of the PI to clearly and explicitly articulate the projects innovation and its potential impact on DMD. The projects impact to both DMD research and to individuals with DMD should be articulated, even if clinical impact is not an immediate outcome. Applications that demonstrate exceptional scientific merit but lack innovation and high potential impact do not meet the intent of the IDA.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in 45 CFR 46.102 as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.

This funding opportunity is designed for organizations that provide accredited medical education to healthcare professionals, ensuring their programs meet ethical standards and enhance professional development in specific therapeutic areas.

This project seeks to enhance detainees rights in Tunisia by expanding access to legal aid and improving enforcement of detainee rights in Tunisia. In 2016, Tunisia passed wide-ranging reforms of its Criminal Procedure Code (CPC). Act 2016-5 (Law 5) enacting article 13 of the CPC gave arrestees in police custody the right to legal counsel and significantly reduced the duration of legal pre-charge detention from 72 to 48 hours. By the order of public prosecutor and when justified, pre-charge detention could be extended with 48 hours for felonies and 24 hours for misdemeanors. In parallel, the anti-terrorism law of 2015 allows prosecutors and police to hold suspects for the first 48 hours without access to a lawyer and extends the duration of pre-charge custody to five days extendable two times for a total of 15 days. Since Law 5 came into force, its application has been uneven. This project seeks to ensure that the rights granted to civilians in Tunisia by Law 5 and criminal procedures proposing alternatives to detention, inter alia, bail provisions, are enforced consistently during the pre-trial phase.

The Healing and Response Teams Special Initiative (Assistance Listing # 16.029) was created in response to recommendations made by the Not Invisible Act Commission (NIAC). This special initiative will support the creation, training, and sustainability of Healing and Response Teams (HRT) using a Tribal-based model of care to respond to Missing or Murdered Indigenous People (MMIP) cases related to domestic violence, dating violence, sexual assault, stalking, and sex trafficking. Within the first nine (9) months of the project, in coordination with OVW, the recipient will identify, make subawards to, and collaborate with three subrecipients acting as pilot sites.

This funding opportunity is designed to support K-12 schools, colleges, universities, and local governments in Michigan in enhancing educational programs about Native American history and culture, revising offensive mascots, and promoting mutual respect.

This notice announces the availability of funds for fiscal year (FY) 2024 and solicits applications from community-based and non-profit organizations, institutions of higher education, and Tribal entities to compete for financial assistance through the Outreach and Assistance for Socially Disadvantaged Farmers and Ranchers and Veteran Farmers and Ranchers Program (hereinafter referred to as the 2501 Program). The term veteran, as used in this program, refers to military veterans. The overall goal of the 2501 Program is to encourage and assist underserved farmers and ranchers, military veteran farmers and ranchers, and beginning farmers and ranchers with owning and operating farms and ranches and in participating equitably in the full range of agricultural, forestry, and related programs offered by USDA. It also includes projects that develop underserved youths' interest in agriculture. In partnership with the OPPE, eligible entities may compete for funding on projects that provide education and training in agriculture, agribusiness, forestry, agricultural-related services, and USDA programs, and to conduct outreach initiatives designed to accomplish those goals. This partnership includes working closely with OPPE, attend OPPE-led events in your proposed service territory, and collaborate with USDA Service Centers located in your state (Farm Service Agency, Natural Resources Conservation Service, and Rural Development).

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinsons research. This award mechanism supports the full spectrum of research from basic science through clinical research.

With this solicitation, OJJDP seeks to provide funding to communities to develop coordinated and comprehensive community-based approaches to help children and their families who are exposed to violence build resilience, restore their safety, heal their social and emotional wounds, and prevent future violence and delinquency. Funding can be used to develop and/or enhance support services for children exposed to violence to reduce the adverse impact of violence on youth, families, and communities, and to help family-serving organizations better recognize and help families at risk for exposure to violence.

The National Endowment for the Humanities (NEH) Office of Challenge Programs is accepting applications for Graduate Education in the Humanities: A National Convening, a cooperative agreement to plan and host a national convening to evaluate the current state of graduate education in the humanities, to make recommendations for programs to prepare graduate students for a variety of humanities-related careers, and to develop a roadmap that articulates a strategic vision for graduate education in the humanities. The project will be funded through a combination of federal matching funds and related fundraising from non-federal third parties.

The purpose of this award is to help EXBS partners in the Western Hemisphere build capacity to implement and enforce strategic trade controls and related mechanisms (e.g., foreign direct investment screening regimes) to mitigate proliferation risks.

With this solicitation, OVC seeks to award a 36-month cooperative agreement to one lead organization that will (1) fund (through a competitive process) subawards to communities severely affected by violence to establish trauma recovery centers , and (2) provide technical assistance to the subawardees to support operation of the centers. The trauma recovery centers funded under this demonstration project will address crime victimization and support access to victims compensation, crime victims rights enforcement, trauma recovery, and healing. Subawardees will be expected to design centers to provide services to crime victims who traditionally do not seek victims services, assistance, or counseling, or are historically underserved. This demonstration is intended to span 5 years (60 months total) via an initial 3-year budget allocation under this solicitation, with the potential for noncompetitive continuation funding as the project moves from year 3 to year 5 of its implementation.

The Bureau of International Narcotics and Law Enforcement Affairs of the U.S. Department of State announces an open competition for organizations to submit applications to carry out a project to increase judicial transparency, independence, and efficiency in Mongolia.